MOTRIN CAPLET TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

IBUPROFEN

Pieejams no:

MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

ATĶ kods:

M01AE01

SNN (starptautisko nepatentēto nosaukumu):

IBUPROFEN

Deva:

200MG

Zāļu forma:

TABLET

Kompozīcija:

IBUPROFEN 200MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

24/50

Receptes veids:

OTC

Ārstniecības joma:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0108883004; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2016-01-22

Produkta apraksts

PRODUCT MONOGRAPH
MOTRIN
®
200 mg
Ibuprofen Tablets USP, 200 mg
MOTRIN
®
Caplet
Ibuprofen Tablets USP, 200 mg
MOTRIN
®
Gelcaps
Ibuprofen Tablets USP, 200 mg
MOTRIN
®
300 mg
Ibuprofen Tablets USP, 300 mg
MOTRIN
®
400 mg
Ibuprofen Tablets USP, 400 mg
Non-Steroidal Anti-inflammatory Drug
Analgesic, Antipyretic Agent
McNeil Consumer Healthcare
Division of Johnson & Johnson Inc.
88 McNabb Street
Markham, Canada
L3R 5L2
Date of Preparation:
May 10, 2002
Date of Revision:
February 26, 2015
Control # 181377
_ _
_Page 2 of 41_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
SPECIAL HANDLING INSTRUCTIONS
.......................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
.........................................................